New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
08:03 EDTABAXAbaxis receives CLIA waiver for cpillary sampling for cholesterol, HDL
Abaxis announced the Food and Drug Administration granted CLIA waived status for capillary draw for CHOL, HDL and TRIG. Combined with existing CLIA waived tests for liver diagnostics using capillary samples, Abaxis now has two complete Lipid Panels which can be used by healthcare professionals to diagnose, treat and monitor hyperlipidemia patients using a sample obtained from either venous blood or a capillary draw. Obtaining CLIA waived status for capillary sampling is an important step in bringing comprehensive care closer to the patients in the U.S.
News For ABAX From The Last 14 Days
Check below for free stories on ABAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
07:08 EDTABAXLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use